Dose-related effect of the oxytocin fragment (prolyl-leucyl-glycinamide) on ?-MPT-induced catecholamine disappearance and serotonin level in rat brain.

Szabó G, Kovács GL, Baláspiri L, Telegdy G

Neurochemistry international1 Jan 1981Cited by 6 (Europe PMC)

PMID20487841DOI10.1016/0197-0186(81)90062-0PepBankPUB-20487841

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats, PLG increased dorsal hippocampal noradrenaline levels 30 min after administration.
In plain wordsIn rats, PLG raised noradrenaline levels in the dorsal hippocampus 30 min after administration.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseDorsal hippocampal noradrenaline
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The noradrenaline level of the dorsal hippocampus was increased 30 min after a dose of 3.5 x 10(?10) mol Pro-Leu-Gly-NH(2).
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784101
02AnimalAnimal study (in vivo)Mechanism
In rats, PLG increased dorsal hippocampal dopamine levels.
In plain wordsIn rats, PLG raised dopamine levels in the dorsal hippocampus.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseDorsal hippocampal dopamine
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The dopamine level was increased in the dorsal hippocampus and in the striatum.
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784102
03AnimalAnimal study (in vivo)Mechanism
In rats, PLG increased striatal dopamine levels.
In plain wordsIn rats, PLG raised dopamine levels in the striatum.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseStriatal dopamine
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The dopamine level was increased in the dorsal hippocampus and in the striatum.
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784103
04AnimalAnimal study (in vivo)Mechanism
In rats, PLG increased hypothalamic serotonin levels.
In plain wordsIn rats, PLG raised serotonin levels in the hypothalamus.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseHypothalamic serotonin
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The serotonin level was increased in the hypothalamus, in the striatum and decreased in the dorsal hippocampus.
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784104
05AnimalAnimal study (in vivo)Mechanism
In rats, PLG increased striatal serotonin levels.
In plain wordsIn rats, PLG raised serotonin levels in the striatum.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseStriatal serotonin
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The serotonin level was increased in the hypothalamus, in the striatum and decreased in the dorsal hippocampus.
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784105
06AnimalAnimal study (in vivo)Mechanism
In rats, PLG decreased dorsal hippocampal serotonin levels.
In plain wordsIn rats, PLG lowered serotonin levels in the dorsal hippocampus.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseDorsal hippocampal serotonin
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The serotonin level was increased in the hypothalamus, in the striatum and decreased in the dorsal hippocampus.
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784106
07AnimalAnimal study (in vivo)Mechanism
In rats challenged with methyl-p-tyrosine, each PLG dose accelerated striatal dopamine disappearance.
In plain wordsIn rats challenged with methyl-p-tyrosine, each PLG dose accelerated dopamine disappearance in the striatum.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseStriatal dopamine disappearance
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The catecholamine disappearance following 350 mg/kg of ?-methyl-p-tyrosine indicated an accelerated dopamine disappearance in the striatum for each dose studied, while the hypothalamic noradrenaline disappearance was inhibited by a dose of 3.5 x 10(?11) mol of Pro-Leu-Gly-NH(2).
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784107
08AnimalAnimal study (in vivo)Mechanism
In rats challenged with methyl-p-tyrosine, PLG inhibited hypothalamic noradrenaline disappearance.
In plain wordsIn rats challenged with methyl-p-tyrosine, PLG slowed noradrenaline disappearance in the hypothalamus.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseHypothalamic noradrenaline disappearance
Study
ratn: not reported in source
cerebral monoamine metabolism
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · lateral cerebral ventricleAs given in this study (rat).
Source sentences
Summary
The catecholamine disappearance following 350 mg/kg of ?-methyl-p-tyrosine indicated an accelerated dopamine disappearance in the striatum for each dose studied, while the hypothalamic noradrenaline disappearance was inhibited by a dose of 3.5 x 10(?11) mol of Pro-Leu-Gly-NH(2).
1 context sentence(design, population, supporting numbers)
Summary · context
Graded doses of Pro-Leu-Gly-NH(2) (3.5 x 10(?12), 3.5 x 10(?11), 3.5 x 10(?10) or 3.5 x 10(?9) mol) were administered into the lateral cerebral ventricle of rats.
Report a problemFND-2048784108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:54 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.